Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $36.00

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its target price lifted by Truist Financial from $30.00 to $36.00 in a research report sent to investors on Monday morning,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages have also issued reports on CPRX. Citigroup upped their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $30.50.

Catalyst Pharmaceuticals Stock Down 1.0 %

NASDAQ CPRX opened at $22.80 on Monday. The firm has a market cap of $2.72 billion, a P/E ratio of 19.32, a price-to-earnings-growth ratio of 3.67 and a beta of 0.75. The company’s 50 day moving average is $20.93 and its 200-day moving average is $18.26. Catalyst Pharmaceuticals has a 12-month low of $12.90 and a 12-month high of $24.27.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the sale, the director now directly owns 348,874 shares in the company, valued at approximately $7,012,367.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the sale, the director now directly owns 348,874 shares in the company, valued at $7,012,367.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Steve Miller sold 150,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the sale, the insider now directly owns 675,124 shares of the company’s stock, valued at $13,738,773.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of CPRX. Oppenheimer & Co. Inc. acquired a new stake in Catalyst Pharmaceuticals during the 1st quarter valued at approximately $805,000. Sei Investments Co. lifted its position in Catalyst Pharmaceuticals by 64.3% during the first quarter. Sei Investments Co. now owns 83,360 shares of the biopharmaceutical company’s stock valued at $1,329,000 after purchasing an additional 32,621 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in Catalyst Pharmaceuticals in the second quarter valued at $258,000. Integral Health Asset Management LLC purchased a new stake in Catalyst Pharmaceuticals in the second quarter valued at $4,260,000. Finally, Vanguard Group Inc. grew its position in Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after purchasing an additional 860,244 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.